paritaprevir (viekira pak) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Paritaprevir is a potent inhibitor of the NS3/4A protease that rapidly and consistently suppresses HCV. Paritaprevir is metabolized by the Cytochrome P450 isoform 3A (CYP3A); therefore, ritonavir was used concurrently to increase plasma concentrations and to prolong the half-life of this agent allowing for once-daily dosing. Several antiviral regimens combining paritaprevir with other agents have shown impressive results, tolerable side effects, and importantly, provided support of ‘all-oral’ interferon-free regimens against HCV. Paritaprevir monotherapy is discontinued now but paritaprevir is used as a component of Viekira Pak and Technivie for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection.   NCATS

Chemistry

  • SMILES: CC1=NC=C(N=C1)C(=O)N[C@H]2CCCCCC=C[C@@H]3C[C@]3(NC(=O)[C@@H]4C[C@H](CN4C2=O)OC5=NC6=CC=CC=C6C7=CC=CC=C57)C(=O)NS(=O)(=O)C8CC8
  • InChIKey: UAUIUKWPKRJZJV-QPLHLKROSA-N
  • Mol. Mass: 765.877
  • ALogP: 3.64
  • ChEMBL Molecule:
    paritaprevir  
More Chemistry

Pharmacology

Combination drugs

( ritonavir (Norvir), ombitasvir (Viekira Pak), paritaprevir (viekira pak) )
|
( ritonavir (Norvir), ombitasvir (Viekira Pak), paritaprevir (viekira pak), dasabuvir (Exviera) - other names: dasabuvir, ombitasvir, paritaprevir, and ritonavir, viekira xr )

Alternative names

(2r,6s,12z,13ar,14ar,16as)-n-(cyclopropanesulfonyl)-6-[(5-methylpyrazine-2-carbonyl)amino]-5,16-dioxo-2-[(phenanthridin-6-yl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5h)-carboxamide | abt-450 | ombitasvir / paritaprevir / ritonavir | paritapravir | paritaprevir | paritaprevir dihydrate | veruprevir | viekira pak

Organizations (29)

Research & Development (29)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (17)

Approved Indications (3)


 

Hepatitis C

Hepatitis C, Chronic (approved 2015)

Infections

Experimental Indications - Clinical Trial Phases 1-4 (17)


 

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Fibrosis (Phase 3)

Genotype (Phase 3)

Healthy Volunteers (Phase 1)

Hepacivirus (Phase 4)

Hepatitis B (Phase 2/Phase 3)

Hepatitis C (Phase 4)

Hepatitis C, Chronic (Phase 4)

Hepatitis Viruses (Phase 4)

HIV (Phase 3)

HIV Infections (Phase 2)

Infections ()

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 4)

Liver Cirrhosis (Phase 3)

Pharmacology (Phase 1)

Renal Insufficiency, Chronic (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 76
  • # of Trial Organizations: 29

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue